本報告已在2011年07月19日停止出版。
在全球經濟起伏不定當中， Rx 醫藥的全球市場依舊以平均年率 7.3% 的速度成長，此報告書預測其市場規模將在 2008 年達到 6,558 億美金的大關。專門彙整並提供全球專業市調公司針對情報通訊、生物、化學、金融等主要產業所出版之報告書的 Takeda Pacific（東京都港區），詳盡地調查與分析 Rx 醫藥的全球市場現況與至 2008 年前的未來趨勢，並有系統地出版綜合報告書 "The Global Rx Drug Market Outlook to 2008 - - Alliances, Pipelines, Medicines and Trends" 。
此報告書使用包括 49 張圖表在內的 123 頁篇幅，除了說明至 2008 年前的全球處方箋市場展望、高銷售量的 276 種醫藥；也分析最暢銷醫藥與市場、合作關係、疾病人口；此外也提供販賣管道、市場動向、大規模醫藥企業的 R＆D 活動等情報。此報告書的概略架構如下所示。
1. 疾病人口與 Rx 醫藥市場
2. 主要 Rx 醫藥的提供企業
3. 醫藥販賣管道、價格、成本
4. 醫藥企業的合夥關係與 M＆A 動向
- 合夥關係/合作/ M＆A
- 合作與 M＆A 的主要相關事項
5. 專利到期與新藥
- 專利即將到期所帶來的影響
- 2003 年研發進入最終階段的醫藥
6. 全球醫藥規範團體
- R＆D 與許可程序
- EU 的醫藥許可
- 日本的醫藥許可
- 全球各地在醫藥規範上的課題
7. Rx 醫藥全球市場的規模與 2008 年以前的展望
- 開發中國家的 Rx 醫藥市場規模
- 前 276 大各疾病/獲利的 Rx 醫藥全球市場規模
- 前 6 大市場區塊/細分市場區塊
8. 尚需檢討的事項與結論
- 使用醫藥企業的疾病人口統計
- 規範、許可、R＆D、國際許可程序
- 醫藥專利到期的期限與新藥
- 醫藥價格與販賣管道
- 醫藥企業的合作關係與 M＆A
- Rx 醫藥的市場規模
- 最暢銷的 Rx 醫藥
- 檢討課題
Abstract
This report is about the global market for prescription drugs and estimates the market outlook to 2008. Readers receive detailed data and analysis about important global pharmaceutical industry developments. The research report discusses key industry activities including alliances, disease demographics to target major diseases, distribution channels and market trends.
The research study shows that companies are facing challenging times ahead as drug patent expirations approach and lists patent expirations to 2008. The development of new drug pipelines and how companies can get their drugs approved around the globe are also key challenges that the pharmas must face. The report discusses what pharma companies must do to market and distribute their approved products to patients around the world.
While the global economy has had its ups and downs, this report projected that the market will grow to about $655.8 billion in 2008 and will grow at a rate of about 7.3% (CAGR).
The pharmaceutical industry faces numerous challenges that could be helped with newer business approaches. This report looks at the industry from the viewpoint of leading disease categories and reveals what the key health issues are through disease demographic data from around the globe. This report analyzes the disease categories of the top 276 drug products and ranks the best selling areas and products. This interesting data is projected to 2008.
Pharma and biotech industry executives, product managers, marketers, planners, entrepreneurs, VCs, investors, academic researchers and consultants would find this report a useful information source. The report discusses the numerous pharma industry topics with interesting and useful findings. Thirty-two tables and seventeen figures illustrate the findings. Detailed information about the business and R&D activities of the top pharma companies is listed in many areas of this report.
About the Publisher
Consultants at Takeda Pacific developed this report. The company provides business consulting that focuses on facilitating business development and market research projects. The business projects may involve European, Japanese and North American Life Science companies. Since its founding in late 1992, TP has reviewed or analyzed over 2,900 Life Science and Technology firms for its clients.
During the past ten years, Takeda Pacific has produced over 49 industry reports about emerging technology companies and markets. Takeda Pacific also offers follow-up consulting or custom research consulting to assist in your business development or market assessment projects.
Table of Contents
1.Disease Demographics and the Rx Drug Market
- Pharmaceutical Planning and Disease Statistics
- The Scale of Major Disease Populations
- Health Risks and Death Linked to `Modern Lifestyle
2.Leading Rx Drugs, Revenues and Drug Companies
- The Leading Twenty Prescription Drugs
- Leading Twenty Rx Drugs by Disease Categories
- Leading Twenty Rx Drugs by Top Pharma Companies
- The Best Selling 276 Prescription Drugs
- The Best Selling Drugs by Disease Categories
3.Drug Market Distribution, Price and Cost Arrangement
- Approaches to Regional Price Setting
- A Case Study of a Drug Distribution Channel
- Distribution Supply Chain and Distributors
- Example of How Rx Drugs Reach Patients (HMO)
4.Pharma Partnering and M&A Trends
- Review of Pharmaceutical Partnerships
- Comparing Alliances and M&As
- Key Findings About Alliances and M&As
- Background to the Following Data Tables
5.Patent Expiries and New Drug Pipelines
- The Impact of Nearing Patent Expirations
- Late Stage Drug Pipeline in 2003
6.Navigating World Drug Regulatory Organizations Drug
- R&D and Regulatory Approval Processes
- Drug Approvals in the USA (North America)
- Overview of the Drug Approval Process in the
- USA (FDA)
- Drug Approvals in the European Union (EU)
- Overview of the Drug Approval Process in the
- European Union
- `Mutual Recognition Principle
- The Centralized Approval Procedure
- Decentralized Approval Procedure
- Drug Approvals in Japan
- Overview of the Drug Approval Process in Japan
- Applications for Approval of Drugs Manufactured
- Outside of Japan
- Japans Priority Review System
- The Orphan Drug Designation
- Regional Drug Regulatory Issues to Consider
- USA (North America)
- The European Union
- In Japan
7.The Global Rx Drug Market Size and Outlook to 2008
- Rx Drug Market Size of the Developed World
- Selected Top 276) Global Rx Drug Market Size by
- Disease and Revenues
- Top Six Market Segments and Subsegments
8.Conclusions and Issues to Consider
- Drug Companies Use Disease Demographics
- Epidemiology Based Pharmaceutical Planning Large
- Disease Populations Point to Potential Marketing
- Opportunities
- Health Risk Factors Lead to Sickness & Death
- Key Points about Global Regulators and Issues
- Need for Government Drug Regulatory Approval
- International Drug R&D and Approval Processes
- Regulatory Trends
- Drug Patent Expiration Dates and New Drug
- Pipeline Patent Expirations Looming to
- Cause Big Losses Current Drug R&D
- Pipeline is Weak
- Drug Pricing & Distribution Arrangements
- Pricing Arrangements
- Drug Distribution Supply Chain
- Pharma Alliances and M&As
- Alliance Trends
- Rx Drug Market Size
- Best Selling Rx Drugs
- Issues to Consider
9.Appendix
- Pharmaceutical Business Glossary
- Contacts to the Top 55 Pharma Companies
- Links to Worldwide Drug Regulatory Organizations
List of Tables
- Table 1. Major Disease Populations by Annual New Patients
- Table 2. Major Disease Populations by Total Existing Patients
- Table 3. Disease Populations in the Developed World
- Table 4. Major Health Risk Factors Leading to Death
- Table 5. Leading 20 Rx Drugs Global Sales ($M)
- Table 6. Leading 15 Disease Categories by Global Sales
- Table 7. Disease Category Definitions Used in this Section
- Table 8. Rx Drugs by Disease Indication and Global Sales
- Table 9. Rx Drug Pricing Tiers and Channels by Region
- Table 9. Rx Drug Pricing Tiers and Channels by Region
- Table 10. Model of US Pricing for Brand Name Rx Drugs
- Table 11. Top Level of US Wholesale Rx Drug Distribution Channel
- Table 12. Details of the US Retail Pharmacy Channel
- Table 13. Key Rx Drug Distributors by International Region
- Table 14. Map of Pharma Alliances and M&As
- Table 15. Pharma Strategic Alliances and M&As by MajorDisease
- Table 16. Alliances and M&As, 2003
- Table 17. Alliances and M&As, 2002
- Table 18. Alliances and M&As, 2001
- Table 19. Alliances and M&As, 2000
- Table 20. Summary of Drug Patent Expirations and Lost Revenues
- Table 21. Drug Patent Expirations to 2008
- Table 22. Drug Patent Expirations by Disease Category and Indication
- Table 23. Drug Pipeline by Clinical Phase in 2003
- Table 24. Drug Pipeline Summary by Disease for 2003
- Table 25. Late Stage Rx Drug Development Pipeline (2003)
- Table 26. Relationship of Drug Regulation to Drug Development
- Table 27. Total Audited World Rx Drug Sales by Regions, 2002
- Table 28. Estimated Global Rx Drug Sales by Regions, 2002 - 2008
- Table 29. Top 10 Products in 2002 Global Rx Drug Sales
- Table 30. Top 276 Human Rx Drug Global Market Size Sorted by 2003 Revenues ($M) and Disease Segments (Summary), 2002-2008E
- Table 31. Top 276 Human Rx Drug Global Market Size Sorted by CAGR and Disease Segments (Summary), 2002-2008E
- Table 32. Top 276 Human Rx Drug Global Market Size by Disease (Detail) ($M) 2002-2008E
List of Illustrations
- Figure 1. An Rx Drug Distribution Arrangement
- Figure 2. Map of Strategic Alliances and M&As
- Figure 3. Selected M&As by Valuation ($M)
- Figure 4. Pharma Strategic Alliances and M&As by Major Disease
- Figure 5. Navigating the Drug R&D and Approval Process
- Figure 6. The US FDA New Drug Approval Process Flowchart
- Figure 7. EU Centralized Drug Approval Procedure Flowchart
- Figure 8. EU Decentralized New Drug Approval Procedure Flowchart
- Figure 9. Japan MHLW New Drug Approval Flowchart
- Figure 10. Estimated Selected (Top 276) Human Rx Drug Global Market Size by Revenues ($M) and Disease Segments, 2002-2008E
- Figure 11. Comparison of Disease Segment Market Shares for the Selected (Top 276) Global Human Rx Drug Market, 2002 and 2008
- Figure 12. Market Size by the Estimated `Cardiovascular Segment Revenues, 2002-2008
- Figure 13. Market Size by Estimated `CNS Subsegment Revenues, 2002-2008
- Figure 14. Market Size by Estimated `Infections Subsegment Revenues, 2002-2008
- Figure 15. Market Size by Estimated `Respiratory & Allergy Subsegment Revenues, 2002-2008
- Figure 16. Market Size by the Estimated `GastrointestinalSubsegment Revenues, 2002-2008
- Figure 17. Market Size by the Estimated `Cancer Subsegment Revenues, 2002-2008
